Court Forces Swiss Government to Disclose Unredacted COVID-19 Vaccine Contracts

The era of pandemic-era opacity is officially over. In a landmark victory for public oversight, the Swiss Federal Administrative Court has crushed the Federal Office of Public Health’s (FOPH) attempts to keep COVID-19 vaccine contracts hidden behind thick black redaction bars. This ruling forces the government to lay bare the unvarnished truth of its dealings with pharmaceutical giants Moderna and Novavax. For years, the FOPH stonewalled journalists and transparency advocates, rejecting access requests as recently as late 2023. Now, the government has waved the white flag, confirming it will not lodge an appeal against the transparency mandate. This isn't just a legal win; it is a seismic shift in Swiss governance that demands total clarity on how taxpayer billions were deployed during the nation's greatest modern crisis. The court has sent a clear message: in a democracy, the public’s right to know outweighs a department's desire for discretion.

A staggering $980 million—nearly a billion dollars—was funneled into a single manufacturer to secure Switzerland’s mRNA supply. Newly revealed data shows that the FOPH committed to 31 million doses of the Moderna vaccine at a premium price of approximately $32 per dose. This massive financial exposure highlights the sheer scale of the procurement scramble that defined 2020 and 2021. While the Moderna deal dominated the budget, the government also diversified with protein-based alternatives, paying $22 per dose for one million Novavax shots, totaling another $20 million. These figures represent a massive transfer of public wealth to the private sector, and until now, the specific terms governing these payments remained a state secret. By exposing these unit prices and total commitments, the court ruling allows the Swiss public to finally audit the 'pandemic premium' paid by the Confederation compared to its European neighbors.

The FOPH’s primary shield against transparency has been the fear of a 'negotiating disadvantage' in future crises. Government officials argued that if vaccine manufacturers knew the specific terms Switzerland accepted, they would hold the country to ransom during the next pandemic. However, the court has effectively dismantled this narrative. Previously, in 2022, the FOPH released heavily censored contracts with Pfizer, Janssen, AstraZeneca, and CureVac, claiming that full disclosure would jeopardize Switzerland's standing on the global stage. Critics argue this secrecy served the interests of Big Pharma more than the Swiss taxpayer. By refusing to appeal the court's decision, the FOPH implicitly acknowledges that the public interest in financial accountability now surpasses the hypothetical risks of future procurement. This sets a powerful precedent: commercial sensitivity can no longer be used as a permanent gag order on government spending.

Switzerland now stands at a crossroads of radical transparency that could redefine the relationship between the state and its citizens. The disclosure of these unredacted contracts is not merely a look back at the chaos of 2020; it is a roadmap for future government conduct. As the FOPH prepares to release the full details of the Moderna and Novavax agreements, the focus shifts to the Army Pharmacy and the logistics of the rollout. What other clauses—indemnity, delivery timelines, or quality guarantees—have been hidden from view? This ruling ensures that when the next health emergency strikes, the 'emergency' label cannot be used to bypass the Transparency Act. The Swiss people have proven that they will not accept a 'trust us' approach to billion-dollar expenditures. Moving forward, the FOPH must operate under the assumption that every contract signed is a contract that will eventually be read by the public.